公开(公告)号：WO2007101833A1

公开(公告)日：2007-09-13

申请号：PCT/EP2007/052035

申请日：2007-03-05

Applicant: AKZO NOBEL N.V. ,  MEIJER, Dirk Thomas ,  VAN STRIEN, Cornelis Johannes Govardus

Inventor： MEIJER, Dirk Thomas ,  VAN STRIEN, Cornelis Johannes Govardus

IPC: C02F1/26 ,  C02F1/28 ,  C02F9/00 ,  B01D11/04 ,  B01D15/00

CPC classification number: B01D11/04 ,  B01D15/00 ,  B01J20/18 ,  B01J20/20 ,  B01J20/26 ,  B01J20/261 ,  B01J20/267 ,  B01J20/28052 ,  B01J20/28078 ,  B01J20/28097 ,  C02F1/26 ,  C02F1/28 ,  C02F1/281 ,  C02F1/283 ,  C02F1/285 ,  C02F1/288 ,  C02F9/00

Abstract: The invention pertains to a process for the removal of liquid, gaseous and/or dissolved constituents from a process stream comprising the steps of a) contacting a process stream with a porous material having pores with an average diameter of 0.01 to 50 µm wherein an extraction liquid is immobilized; and b) subsequently contacting the resulting process stream with an adsorbent.

Abstract translation: 本发明涉及从工艺流中除去液体，气态和/或溶解成分的方法，包括以下步骤：a）使工艺流与具有平均直径为0.01至50μm的孔的多孔材料接触，其中提取 液体固定; 和b）随后使所得工艺流与吸附剂接触。

公开(公告)号：WO1992015316A1

公开(公告)日：1992-09-17

申请号：PCT/NL1992000036

申请日：1992-02-24

Applicant: RIJKSUNIVERSITEIT TE GRONINGEN ,  JANSEN, Robert, Walter ,  MEIJER, Dirk, Klaas, Fokke ,  MOLEMA, Grietje ,  DE CLERCQ, Erik, Désiré, Alice ,  PAUWELS, Rudi, Wilfried, Jan ,  SCHOLS, Dominique

Inventor： RIJKSUNIVERSITEIT TE GRONINGEN

IPC: A61K37/02

CPC classification number: A61K38/38 ,  C07K1/1077

Abstract: The invention relates to pharmaceutical preparations which are suitable for treating or curing viral infections, including influenza and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can also be used to inhibit fusion of virus-infected cells with non-infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active, which modified proteins or polypeptides have acquired an additional net negative charge by derivatisation of their amino groups and/or other basic functional groups with a reagent which prevents protonation of basic amino acids and/or other basic functional groups or replaces said basic amino acids and/or other basic functional groups by one or more functional groups having a negative charge, and to modified proteins and polypeptides themselves and the preparation and use thereof.

Abstract translation: 本发明涉及适用于治疗或治愈病毒感染的药物制剂，包括流感和免疫缺陷病，如逆转录病毒感染，包括艾滋病和艾滋病相关疾病，也可用于抑制病毒感染细胞与非感染性细胞的融合 感染的细胞，其制备物含有修饰的蛋白质或多肽作为有助于其作用的活性物质或物质，或作为其他物质的载体，其也是活性的，所述修饰的蛋白质或多肽已经通过其氨基的衍生获得额外的净负电荷 和/或其它碱性官能团，其具有防止碱性氨基酸和/或其它碱性官能团质子化的试剂，或者通过一个或多个具有负电荷的官能团替代所述碱性氨基酸和/或其它碱性官能团，并且 修饰的蛋白质和多肽本身及其制备和用途。

公开(公告)号：WO2005106338A1

公开(公告)日：2005-11-10

申请号：PCT/NL2005/000314

申请日：2005-04-26

Applicant: MEIJER, Dirk-Paul, Marcel

Inventor： MEIJER, Dirk-Paul, Marcel

IPC: F24D3/14

CPC classification number: F24D3/142

Abstract: Wall, floor or ceiling heating system for a home or office, consisting of a flexible heating line (5), arranged on a base in loops, for a heating medium, which flexible line is accommodated in panels (6) made of a suitable heat-conducting material. The assembly of panels and heating line is covered by a finishing layer (8). The invention is distinguished by the fact that the panels are of a thickness which is at least equal to the diameter of the heating line, the panels are provided along two opposite side edges with a groove (7), which accommodates at least part of the outer circumference of the heating line in such a manner that the heating line is held securely between panels adjoining one another, and that the panels support only the substantially straight part of the heating line.

Abstract translation: 用于家庭或办公室的墙壁，地板或天花板加热系统，由布置在基座上的柔性加热线（5）组成，用于加热介质，该柔性线容纳在由合适的热量制成的面板（6）中 导电材料。 面板和加热线的组装被整理层（8）覆盖。 本发明的特征在于，面板的厚度至少等于加热线的直径，面板沿着具有凹槽（7）的两个相对侧边缘设置，该凹槽容纳至少部分 加热线的外周以使得加热线牢固地保持在彼此相邻的板之间，并且板仅支撑加热线的基本上直的部分。

公开(公告)号：WO0000214A3

公开(公告)日：2000-03-30

申请号：PCT/EP9904067

申请日：1999-06-28

Applicant: NUTRICIA NV ,  SWART PIETER JACOB ,  KUIPERS MARIA ELIZABETH ,  MEIJER DIRK KLAAS FOKKE ,  HAGEMAN ROBERT JOHAN JOSEPH ,  DEN BERG JEROEN JOHANNES MARIA

Inventor： SWART PIETER JACOB ,  KUIPERS MARIA ELIZABETH ,  MEIJER DIRK KLAAS FOKKE ,  HAGEMAN ROBERT JOHAN JOSEPH ,  VAN DEN BERG JEROEN JOHANNES M

IPC: A61K38/16 ,  A61K38/00 ,  A61K38/17 ,  A61K38/40 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P35/00 ,  C07K5/097 ,  C07K5/11 ,  C07K7/06 ,  C07K7/08 ,  C07K14/79

CPC classification number: A61K38/40 ,  A61K38/1709 ,  A61K2300/00

Abstract: The invention relates to a medicament for treatment and/or prevention of infections caused by bacteria, fungi, viri and the like, inflammations and/or tumors, said medicament comprising an active amount of a polycationic peptide or protein, and a buffer for maintaining the pH of treatable tissue within a preselected range.

Abstract translation: 本发明涉及用于治疗和/或预防由细菌，真菌，病毒等，炎症和/或肿瘤引起的感染的药物，所述药物包含活性量的聚阳离子肽或蛋白质，以及用于维持 可处理组织的pH在预选范围内。

公开(公告)号：WO1995005456A1

公开(公告)日：1995-02-23

申请号：PCT/NL1994000189

申请日：1994-08-10

Applicant: RIJKSUNIVERSITEIT TE GRONINGEN ,  POELSTRA, Klaas ,  HARDONK, Machiel, Josephus ,  BAKKER, Winston, Willem ,  MEIJER, Dirk, Klaas, Fokke

Inventor： RIJKSUNIVERSITEIT TE GRONINGEN

IPC: C12N09/16

CPC classification number: C12N9/16 ,  A61K38/00 ,  A61K38/193 ,  A61K45/06 ,  C07K14/51 ,  C12Y301/03001 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.

Abstract translation: 本发明涉及适用于治疗或治疗由内毒素介导的临床并发症的药物组合物，包括败血症。 所述组合物含有适于解毒内毒素的成分，使其对哺乳动物（例如人），特别是对抗宿主抗性降低的患者更少有害。 本发明还涉及适于刺激骨形成的药物组合物，例如， 用于修复断骨或用于预防或治疗代谢性骨疾病如骨质疏松症和骨软化症以及用于减少或抑制不想要的骨形成的药物组合物。 根据本发明的药物组合物涉及在体内调节磷酸酶活性。

公开(公告)号：WO1995005455A1

公开(公告)日：1995-02-23

申请号：PCT/NL1993000171

申请日：1993-08-13

Applicant: RIJKSUNIVERSITEIT TE GRONINGEN ,  POELSTRA, Klaas ,  HARDONK, Machiel, Josephus ,  BAKKER, Winston, Willem ,  MEIJER, Dirk, Klaas, Fokke

Inventor： RIJKSUNIVERSITEIT TE GRONINGEN

IPC: C12N09/16

CPC classification number: C12N9/16 ,  A61K38/00 ,  A61K38/193 ,  A61K45/06 ,  C07K14/51 ,  C12Y301/03001 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. form mending broken bone or for prophylaxis or therapy of osteoporosis and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.

Abstract translation: 本发明涉及适用于治疗或治疗由内毒素介导的临床并发症的药物组合物，包括败血症。 所述组合物含有适于解毒内毒素的成分，使其对哺乳动物（例如人），特别是对抗宿主抗性降低的患者更少有害。 本发明还涉及适于刺激骨形成的药物组合物，例如， 形成修复破骨或用于预防或治疗骨质疏松症和用于减少或抑制不想要的骨形成的药物组合物。 根据本发明的药物组合物涉及在体内调节磷酸酶活性。

公开(公告)号：WO1995028092A1

公开(公告)日：1995-10-26

申请号：PCT/EP1995001461

申请日：1995-04-18

Applicant: GIST-BROCADES B.V. ,  EDENS, Luppo ,  MEIJER, Dirk ,  VAN PARIDON, Petrus, Andreas

Inventor： GIST-BROCADES B.V.

IPC: A23K01/16

CPC classification number: C12N9/00 ,  A23K20/174 ,  A23K20/179 ,  A23K20/189 ,  A23K40/30 ,  A23K50/75 ,  A23L29/06 ,  A23L29/10 ,  A23L33/15 ,  A23L35/10 ,  A23V2002/00 ,  A61K8/06 ,  A61K8/064 ,  A61K8/345 ,  A61K8/375 ,  A61K8/60 ,  A61K8/66 ,  A61Q19/00 ,  C12Y301/00 ,  C12Y301/01003 ,  C12Y301/03 ,  C12Y302/00 ,  C12Y304/00 ,  A23V2250/154 ,  A23V2250/30 ,  A23V2250/642 ,  A23V2250/18 ,  A23V2200/222 ,  A23V2250/192 ,  A23V2250/6406 ,  A23V2250/032 ,  A23V2250/708

Abstract: The present invention describes stable water-in-oil emulsions comprising the following components: water, oil, a labile compound of interest, a stabilizing agent and an emulsifier. The labile compound present in the water phase is stabilized by addition of a stabilizing agent which preferably is a polyol. Specific emulsifiers are described which give rise to stable emulsions in the presence of high amounts of a polyol.

Abstract translation: 本发明描述了稳定的油包水乳液，其包含以下组分：水，油，感兴趣的不稳定化合物，稳定剂和乳化剂。 存在于水相中的不稳定化合物通过加入优选为多元醇的稳定剂来稳定。 描述了在大量多元醇存在下产生稳定乳液的特定乳化剂。

公开(公告)号：WO1993017713A1

公开(公告)日：1993-09-16

申请号：PCT/NL1993000061

申请日：1993-03-15

Applicant: RIJKSUNIVERSITEIT GRONINGEN ,  FRANSSEN, Erik, Johannes, Franciscus ,  MOOLENAAR, Frits ,  MEIJER, Dirk, Klaas, Fokke ,  DE ZEEUW, Dick

Inventor： RIJKSUNIVERSITEIT GRONINGEN

IPC: A61K47/48

CPC classification number: A61K47/62 ,  Y10S530/81 ,  Y10S530/812 ,  Y10S530/815

Abstract: Use of alpha -hydroxy acids and poly- alpha -hydroxy acids as spacer between a therapeutically and/or diagnostically active compound and a soluble macromolecular carrier in pharmaceutical compositions having site-specific delivery. In one embodiment glycolic acid, L-lactic acid or tetra-L-lactic acid is used as spacer between a non-steroidal anti-inflammatory substance and a carrier of low molecular protein (LMWP).

Abstract translation: 在具有位点特异性递送的药物组合物中使用α-羟基酸和聚-α-羟基酸作为治疗和/或诊断活性化合物与可溶性大分子载体之间的间隔物。 在一个实施方案中，乙醇酸，L-乳酸或四-L-乳酸用作非甾体抗炎物质和低分子量蛋白质（LMWP）载体之间的间隔物。